Document is current
Any future updates will be listed below
-
Authors
Binvignat, Marie
Sellam, Jérémie
Berenbaum, Francis https://orcid.org/0000-0001-8252-7815
Felson, David T.
- License Information
-
More Information
Article History
Accepted: 5 July 2024
First Online: 7 August 2024
Competing interests
: M.B. declares that she has received grant support from the French Society of Rheumatology, the Osteoarthritis Foundation and Pfizer ADVANCE 2020 program, and a doctoral fellowship from Sorbonne University. J.S. declares that he has received personal fees from MSD, Pfizer, Abbvie, Fresenius Kabi, BMS, Roche, Chugai, Sandoz, Lilly, Novartis, Galapagos, AstraZeneca, UCB and Janssen, and research grants from Pfizer, MSD, Schwa Medico and BMS. F.B. declares that he has received institutional grants from TRB Chemedica and Pfizer; has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bone Therapeutics, Cellprothera, Galapagos, Gilead, Grunenthal, GSK, Eli Lilly, MerckSerono, MSD, Nordic Bioscience, Novartis, Pfizer, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov and 4P Pharma; has received honoraria for lectures from Expanscience, Pfizer, Viatris; has received payment for expert testimony from Pfizer and Eli Lilly; has received travel support from Nordic Pharma, Pfizer, Eli Lilly and Novartis; and owns stock in and is CEO of 4Moving Biotech, a company developing intraarticular liraglutide for knee osteoarthritis. D.T.F. declares no competing interests.
